Improved Novel VaccIne CombinaTion InflUenza Study
Status:
Terminated
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
A Phase IIb randomised, participant-blinded, placebo-controlled, multi-centre phase IIb
efficacy study in 2030 volunteers aged 65 and over. The study will assess the safety and
efficacy of the co-administration of a viral vectored vaccine, MVA- NP+M1, and the annual
recommended licensed inactivated influenza vaccine (IIV). Within the main cohort 100
participants will be recruited to an immunology sub-cohort.